Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants

Most therapeutic mAbs target the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2. Unfortunately, the RBD is a hot spot for mutations in SARS-CoV-2 variants, which will lead to loss of the neutralizing function of current therapeutic mAbs. Universal mAbs for different variants are ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wan-Ling, Chiang, Chen-Yi, Lai, Szu-Chia, Yu, Chia-Yi, Huang, Yu-Ling, Liao, Hung-Chun, Liao, Ching-Len, Chen, Hsin-Wei, Liu, Shih-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089791/
https://www.ncbi.nlm.nih.gov/pubmed/35290246
http://dx.doi.org/10.1172/jci.insight.157597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089791/
https://www.ncbi.nlm.nih.gov/pubmed/35290246
http://dx.doi.org/10.1172/jci.insight.157597

Ejemplares similares